Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary

被引:74
作者
Mizuno, Mika
Kikkawa, Fumitaka
Shibata, Kiyosumi
Kajiyama, Hiroaki
Ino, Kazuhiko
Kawai, Michiyasu
Nagasaka, Tetsuro
Nomura, Seiji
机构
[1] Nagoya Univ, Grad Sch Med, Dept Obstet & Gynecol, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Japanese Red Cross Nagoya First Hosp, Dept Obstet & Gynecol, Nakamura Ku, Nagoya, Aichi, Japan
[3] Toyohashi City Hosp, Dept Obstet & Gynecol, Toyohashi, Aichi, Japan
[4] Nagoya Univ Hosp, Clin Lab, Div Pathol, Showa Ku, Nagoya, Aichi, Japan
关键词
serous cystadenocarcinoma; stage; residual tumor;
D O I
10.1002/jso.20251
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives: There were a few reports of a large number of patients with clear cell adenocarcinoma (CCA) of the ovary because of the low incidence of CCA. This study compared the clinical factors affecting long-term survival of patients with CCA to those with serous cystadenocarcinoma (SCA). Methods: One hundred and seventy-eight CCA and 311 SCA patients treated between 1987 and 2000 were retrospectively evaluated. Differences in survival rates were calculated using log-rank test and Cox's proportional hazards analysis was used to identify independent prognostic factors. Results: The ratio of stage I was significantly higher than that of SCA. There was no significant difference of 8-year survival rate in each stage between CCA and SCA. However, the patients with stage IIIb or IIIc CCA showed significantly worse prognosis than those with SCA. Positive peritoneal or ascitic cytology, the presence of residual tumor, more than 100 ml ascites were demonstrated to have the significant impact on survival by univariate analysis. Multivariate analysis demonstrated that stage, more than 100 ml ascites, and the presence of residual tumor were significant prognostic factors of CCA overall survival. Conclusions: Distribution of stage and substage differed between CCA and SCA in this study. Thus, substaging is quite important for comparison of prognoses between histologies, and CCA showed poorer prognoses than serous adenocarcinoma in stages IIIb and IIIc.
引用
收藏
页码:138 / 143
页数:6
相关论文
共 19 条
[1]   Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer [J].
Bristow, RE ;
Montz, FJ ;
Lagasse, LD ;
Leuchter, RS ;
Karlan, BY .
GYNECOLOGIC ONCOLOGY, 1999, 72 (03) :278-287
[2]   Long-term results and prognostic factors in patients with epithelial ovarian cancer [J].
Brun, JL ;
Feyler, A ;
Chêne, G ;
Saurel, J ;
Brun, G ;
Hocké, C .
GYNECOLOGIC ONCOLOGY, 2000, 78 (01) :21-27
[3]   THE PROGNOSTIC VALUE OF EARLY CA125 SERUM ASSAY IN EPITHELIAL OVARIAN-CARCINOMA [J].
FISKEN, J ;
LEONARD, RCF ;
STEWART, M ;
BEATTIE, GJ ;
STURGEON, C ;
ASPINALL, L ;
ROULSTON, JE .
BRITISH JOURNAL OF CANCER, 1993, 68 (01) :140-145
[4]   THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA [J].
HOSKINS, WJ ;
MCGUIRE, WP ;
BRADY, MF ;
HOMESLEY, HD ;
CREASMAN, WT ;
BERMAN, M ;
BALL, H ;
BEREK, JS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (04) :974-980
[5]   THE INFLUENCE OF CYTOREDUCTIVE SURGERY ON RECURRENCE-FREE INTERVAL AND SURVIVAL IN SMALL-VOLUME STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
HOSKINS, WJ ;
BUNDY, BN ;
THIGPEN, JT ;
OMURA, GA .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :159-166
[6]   CLEAR CELL ADENOCARCINOMA OF THE OVARY - A CLINICAL ANALYSIS AND COMPARISON WITH SEROUS CARCINOMA [J].
JENISON, EL ;
MONTAG, AG ;
GRIFFITHS, CT ;
WELCH, WR ;
LAVIN, PT ;
GREER, J ;
KNAPP, RC .
GYNECOLOGIC ONCOLOGY, 1989, 32 (01) :65-71
[7]   OVARIAN CLEAR CELL ADENOCARCINOMA [J].
KENNEDY, AW ;
BISCOTTI, CV ;
HART, WR ;
WEBSTER, KD .
GYNECOLOGIC ONCOLOGY, 1989, 32 (03) :342-349
[8]   Survival probability in ovarian clear cell adenocarcinoma [J].
Kennedy, AW ;
Markman, M ;
Biscotti, CV ;
Emery, JD ;
Rybicki, LA .
GYNECOLOGIC ONCOLOGY, 1999, 74 (01) :108-114
[9]   Randomized trial of cisplatin and carboplatin versus cisplatin, vinblastine and bleomycin in ovarian cancer [J].
Kikkawa, F ;
Matsuzawa, K ;
Arii, Y ;
Kawai, M ;
Kobayashi, I ;
Nakashima, N ;
Mizutani, S .
GYNECOLOGIC AND OBSTETRIC INVESTIGATION, 2000, 50 (04) :269-274
[10]   Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial [J].
Markman, M ;
Liu, PY ;
Wilczynski, S ;
Monk, B ;
Copeland, LJ ;
Alvarez, RD ;
Jiang, C ;
Alberts, D .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2460-2465